


# Integrated Drug Discovery

Pharmaron's integrated drug discovery services team leads projects **from hit identification through candidate selection and beyond**. We combine world-class scientific and project leadership with global resources and expertise to offer integrated end-to-end support for the discovery of new therapeutics.



**Integrated Drug Discovery Team**

Our multi-disciplinary leadership team of experienced scientists located in the UK, China and US will lead the projects in close collaboration with our clients.

**Client**

The collective expertise of our seasoned drug hunting team, each member with multi-year industry experience and a proven track record, provides **strategy, decision-making** and **project coordination** to transform ideas into high-quality drug candidates.

Our integrated approach provides scientific excellence combined with efficient delivery.

## Expertise

Our integrated drug discovery team has operated over many years, across **therapeutic areas**, **target types** and **modalities**, successfully advancing projects from hit-finding through preclinical candidate selection into the clinic.

### Therapeutic Areas

- Cancer
- Metabolic diseases
- Cardiovascular diseases
- Inflammation/pain
- Immunologic diseases
- Neurologic diseases
- Rare diseases

### Target Types

- Enzymes
- GPCRs
- Transporters
- Chaperones
- Nuclear receptors
- Transcription factors
- Ion channels
- Phenotypic

### Modalities

- Orthosteric binders
- Allosteric binders
- Covalent binders
- Protein degraders
- Molecular glues
- ADC

## Why work with Pharmaron?

- Leverage the expertise of an experienced, multi-disciplinary scientific leadership team working in close collaboration with your team
- Benefit from nimble and flexible resource allocation, utilizing Pharmaron's comprehensive capabilities, instrumentation, and human resources across the UK, US, and China
- Tap into scientific expertise across all relevant research fields and utilize state-of-the-art technology to facilitate efficient Design-Make-Test-Analyze cycles
- Eliminate the coordination between different service providers and transform Pharmaron's industry leading turnaround times into accelerated drug discovery

## Beyond Preclinical Candidate Selection

Pharmaron excels beyond preclinical selection, offering comprehensive IND-enabling services and clinical development. With a focus on collaboration and proactive regulatory planning, we ensure smooth IND filing through in-house pharmacology, toxicology, manufacturing, and clinical strategies. Our integrated approach streamlines the transition into successful clinical trials.

## Selected publications highlighting our scientists' expertise.

### Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator

Journal of Medicinal Chemistry. 2024. [↗](#)

Journal of  
**Medicinal  
Chemistry**

pubs.acs.org/jmc

Drug Annotation

Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator

### Discovery of a novel series of selective macrocyclic PKC $\theta$ inhibitors

Bioorganic & Medicinal Chemistry Letters. 2024. [↗](#)



Bioorganic & Medicinal Chemistry Letters  
Volume 100, 1 March 2024, 129630



Discovery of a novel series of selective macrocyclic PKC $\theta$  inhibitors

### A novel dual ATM/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors

Molecular Cancer Therapeutics. 2024. [↗](#)

MOLECULAR CANCER THERAPEUTICS | SMALL MOLECULE THERAPEUTICS

A novel dual ATM/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors



### Non-specific binding of compounds in *in vitro* metabolism assays: a comparison of microsomal and hepatocyte binding in different species and an assessment of the accuracy of prediction models

Xenobiotica. 2022. [↗](#)

XENOBIOTICA  
2022, VOL. 52, NO. 8, 943-956  
<https://doi.org/10.1080/00498254.2022.2132426>

 Taylor & Francis  
Taylor & Francis Group

RESEARCH ARTICLE

 OPEN ACCESS  Check for updates

Non-specific binding of compounds in *in vitro* metabolism assays: a comparison of microsomal and hepatocyte binding in different species and an assessment of the accuracy of prediction models

## Talk to us about your drug discovery program today.

